PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: €68.00 through €172.00
Semaglutide EU – Buy Online | In Stock & Ready to Ship
Buy Semaglutide in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for Semaglutide Europe suppliers, looking to buy Semaglutide in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
Semaglutide is a synthetic GLP-1 receptor agonist peptide and the most widely referenced incretin research compound in modern metabolic science — studied extensively across Europe and globally for its influence on insulin signalling, glucose regulation, appetite biology, and pancreatic beta cell function. Research institutions and laboratories across the EU can source verified, research-grade Semaglutide in Europe with fast domestic dispatch, cold-chain packaging, and full batch documentation included.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch Across EU & Europe | EU Peptides Stock
Semaglutide is a 31-amino acid synthetic analogue of GLP-1 — the incretin hormone naturally released from intestinal L-cells after eating. It was developed with specific structural modifications that make it highly resistant to the DPP-4 enzyme, which normally breaks down native GLP-1 within minutes. The result is a research peptide with a half-life of approximately seven days — one of the longest-acting GLP-1 receptor agonists available to European research laboratories today.
Its exceptional receptor selectivity, long half-life, and extensively documented pharmacological profile have made Semaglutide the reference GLP-1R agonist in metabolic and incretin research — and the standard compound against which newer dual and triple receptor peptides like Tirzepatide and Retatrutide are compared. Research interest in Semaglutide peptides across Europe continues to grow alongside expanding EU-based investigation into metabolic disease, diabetes biology, obesity research, and cardiovascular science.
In controlled pre-clinical and laboratory research settings, Semaglutide in Europe is used across a wide range of metabolic and physiological research applications:
Insulin Secretion Research — Semaglutide’s primary studied mechanism is glucose-dependent stimulation of insulin secretion from pancreatic beta cells through GLP-1R activation. Studies use it to examine incretin-driven insulin release kinetics, beta cell signalling cascades, and how GLP-1R-mediated secretion compares to direct glucose stimulation in pancreatic cell models.
Pancreatic Beta Cell Biology — Research has examined Semaglutide’s trophic effects on beta cells including influences on cell survival, proliferation, and function — exploring how sustained GLP-1R activation affects beta cell mass and responsiveness in cellular research models.
Glucose Homeostasis Studies — Studies have investigated how Semaglutide influences overall glucose regulation including postprandial glucose dynamics, glucagon suppression, gastric emptying rate, and hepatic glucose output — providing a comprehensive picture of how GLP-1R activation coordinates the metabolic response to nutrient intake.
Appetite and Satiety Research — Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem. EU-based research has examined how it influences appetite-regulating neuropeptide expression, satiety signalling pathways, and food intake behaviour in pre-clinical models.
Body Composition Research — Pre-clinical studies have examined Semaglutide’s effects on body weight, fat mass distribution, and lean mass parameters in animal obesity models — with research documenting some of the most pronounced body composition changes observed with any single-receptor metabolic peptide.
Cardiovascular Research — GLP-1 receptors are expressed in cardiac and vascular tissue. Studies have examined Semaglutide’s influence on endothelial function, lipid metabolism, inflammatory pathway modulation, and cardiovascular metabolic markers in pre-clinical settings.
Gut-Brain Axis Research — Semaglutide has been incorporated into investigations examining gut-brain axis signalling — exploring how peripheral GLP-1R activation communicates with central appetite and reward circuits and how incretin hormones influence broader neurological function.
Comparative GLP-1R Pharmacology — As the most established GLP-1R agonist in research, Semaglutide serves as the reference compound for comparative studies examining newer dual and triple-receptor metabolic peptides — providing a well-characterised baseline against which additional receptor pathways of compounds like Tirzepatide are measured.
Semaglutide has one of the most extensive research profiles of any metabolic peptide available to European laboratories:
Pre-clinical metabolic studies have consistently documented Semaglutide’s influence on body weight and fat mass parameters in animal obesity models — with results exceeding those of earlier GLP-1R agonists and establishing it as a benchmark compound in EU obesity and metabolic biology research.
Pancreatic research has produced a substantial body of work examining Semaglutide’s trophic effects on beta cells — with studies reporting influences on beta cell proliferation, apoptosis resistance, and insulin gene expression, contributing to a detailed mechanistic picture of how sustained GLP-1R activation affects pancreatic biology.
Appetite regulation research has documented Semaglutide’s central nervous system effects in pre-clinical models — characterising its influence on hypothalamic appetite circuits, leptin sensitivity, ghrelin suppression, and reward pathway modulation, making it a comprehensive tool for studying the neurological dimensions of metabolic regulation.
Cardiovascular research conducted across European institutions has examined Semaglutide in pre-clinical cardiac and vascular biology models — exploring its influence on endothelial function, inflammatory markers, and lipid metabolism in cardiovascular tissue.
Its status as the active ingredient in globally recognised prescription metabolic medications has generated an unusually large body of both pre-clinical and clinical research data — making it the most comprehensively documented GLP-1R agonist available as a research tool and the standard reference compound for the entire incretin research field.
| Peptide | Half-Life | Receptor Target | Primary Research Use |
|---|---|---|---|
| Semaglutide | ~7 days | GLP-1R only | Metabolic / glucose / weight research |
| Tirzepatide | ~5 days | GLP-1R + GIPR | Dual incretin research |
| Retatrutide | Emerging | GLP-1R + GIPR + Glucagon | Triple receptor metabolic research |
| Mazdutide | Emerging | GLP-1R + Glucagon | Hepatic / energy expenditure research |
| Native GLP-1 | ~2 minutes | GLP-1R | Acute receptor pharmacology |
| Parameter | Specification |
|---|---|
| Full Name | Semaglutide |
| Also Known As | GLP-1 Analogue / NNC9204-0169 |
| Type | Synthetic GLP-1 Receptor Agonist |
| Sequence | 31-Amino Acid GLP-1 Analogue |
| Molecular Weight | 4,113.64 g/mol |
| CAS Number | 910463-68-2 |
| Purity | ≥99% HPLC & MS Verified |
| Form | White Lyophilised Powder |
| Solubility | Sterile water, bacteriostatic water, PBS pH 7.4 with 0.1% BSA |
| Storage (Powder) | -20°C, stable 24+ months |
| Storage (Reconstituted) | 2–8°C, use within 28 days |
| Available Sizes | 5mg, 10mg, 20mg |
| Dispatch | Fast EU & Europe dispatch — cold-chain packaged |
| Intended Use | Research use only |
Every order of Semaglutide dispatched across the EU and Europe includes:
✅ Batch-Specific Certificate of Analysis (CoA)
✅ HPLC Chromatogram
✅ Mass Spectrometry Confirmation
✅ Sterility & Endotoxin Testing Report
✅ Reconstitution and Storage Protocol
✅ Technical Research Support
Yes — research-grade Semaglutide is available to researchers and institutions across the EU and Europe with fast dispatch and full batch documentation included. Orders are cold-chain packaged to maintain peptide integrity throughout transit. Supplied strictly for laboratory research purposes only.
Semaglutide is the active molecule found in both Ozempic and Wegovy. Research-grade Semaglutide supplied to EU laboratories is provided as a lyophilised powder for controlled scientific investigation only — it is not a pharmaceutical product and cannot substitute for prescription medications, which are manufactured to clinical standards with specific formulations and delivery systems for medical use under physician supervision.
Native GLP-1 is broken down by the DPP-4 enzyme within approximately two minutes of release. Semaglutide was engineered with an amino acid substitution at position 8 and a fatty acid chain conjugated at lysine providing albumin binding and steric protection from DPP-4 — extending its functional half-life to approximately seven days. This makes it far more practical for sustained GLP-1R activation studies than native GLP-1.
Semaglutide is a selective GLP-1R agonist targeting only the GLP-1 receptor pathway. Tirzepatide is a dual GIP/GLP-1 receptor co-agonist that additionally engages GIP receptors. Semaglutide is the preferred EU research tool when isolating pure GLP-1R mechanism effects, while Tirzepatide is used when studying combined incretin receptor pharmacology. Many European research teams use both in parallel to characterise individual versus combined incretin receptor contributions to metabolic outcomes.
Allow the vial to reach room temperature before opening — approximately 10–15 minutes. Add bacteriostatic water or sterile PBS pH 7.4 with 0.1% BSA slowly down the inside vial wall. Swirl gently without shaking until fully dissolved. Typical research concentrations are 0.5–2 mg/mL. Aliquot and store at -20°C for longer-term storage, or refrigerate at 2–8°C and use within 28 days.
A minimum of ≥98% is considered research grade, though ≥99% is strongly preferred for sensitive receptor binding assays, insulin secretion studies, and pre-clinical metabolic experiments across EU research institutions. Lower purity may introduce synthesis byproducts that interfere with GLP-1R binding accuracy. All Semaglutide supplied for European research is independently verified to ≥99% purity.
Orders are dispatched promptly via tracked courier with cold-chain packaging designed to maintain peptide integrity throughout transit across Europe. Delivery timelines vary by destination within the EU — contact us for specific country delivery estimates.
Semaglutide is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It is not a pharmaceutical product and cannot substitute for prescription medications containing Semaglutide. It must be handled by qualified researchers in compliance with applicable EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in vitro or pre-clinical research purposes.
Receive News
